Phase II trial of didemnin-B in advanced epithelial ovarian cancer |
| |
| Authors: | Joanna M. Cain P. Y. Liu David E. Alberts Holly H. Gallion Leslie Laufman Janet O'Sullivan Geoffrey Weiss John N. Bickers |
| |
| Affiliation: | (1) Puget Sound Oncology Consortium, Seattle, WA, USA;(2) Southwest Oncology Group Statistical Center, Seattle, WA, USA;(3) University of Arizona Cancer Center, Tucson, AZ, USA;(4) University of Kentucky Medical Center, Lexington, KY, USA;(5) Columbus CCOP, Columbus, OH, USA;(6) University of Texas Health Science Center at San Antonio, San Antonio, TX, USA;(7) Louisiana State University Medical Center, New Orleans, LA, USA |
| |
| Abstract: | Summary A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer. |
| |
| Keywords: | Didemnin-B ovarian cancer |
| 本文献已被 SpringerLink 等数据库收录！ |
|
